Endometrial cancer is a malignancy arising from the endometrium, the inner lining of the uterus. It is one of the most common gynecologic cancers in developed countries and is often diagnosed after menopause. Early-stage detection is associated with favorable outcomes.
A phase II trial of TAK-007 CAR-NK therapy in R/R B-cell NHL showed a 60.9% overall response rate. Preclinical CAR-NKT therapy eliminated endometrial tumors in models. Optimized costimulatory domains (2B4-DAP12) boosted CAR-NK tumor killing.
Acrivon Therapeutics said its wholly owned laboratory in Watertown received Massachusetts CLIA certification with a full license to conduct patient testing and develop companion diagnostics. The company said the lab is expected to be fully operational in the first half of 2026 and will support targeted therapeutics development.
MSD said sacituzumab tirumotecan improved overall survival and progression-free survival in the Phase III TroFuse-005 trial in endometrial cancer. The study also met its objective response rate endpoint.
Sensei Biotherapeutics dosed the first patient in a Phase 1b/2 trial of PIKTOR (sapanisertib + serabelisib) in HR+/HER2- advanced breast cancer. The multi-node PI3K/AKT/mTOR inhibitor previously showed a 47% overall response rate in a Phase 1b trial.
New research reveals GLP-1 receptor agonists reduce substance use disorders by 14%, lower Parkinson's disease risk after 5-10 years of use, and cut endometrial cancer risk by 66% when combined with progestin therapy.
New research shows cancer survivors who exercise reduce their risk of cancer-related death, while expert panel recommends exercise as essential for older cancer patients during and after treatment.
A comprehensive market report reveals over 180 companies are developing more than 200 PD-1 and PD-L1 inhibitor drugs, with recent fast-track designations and successful Phase III trial results driving expansion in cancer immunotherapy.
The FDA has approved labeling changes to six menopausal hormone therapy products, removing boxed warnings related to cardiovascular disease, breast cancer, and probable dementia that had been in place since 2003.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07605247 |
Tirzepatide in the Treatment of Endometrial Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07595224 |
Postoperative Hypofractionated Whole Pelvic Radiotherapy in Cervical and Endometrial Cancer |
RECRUITING | NA |
| NCT07594327 |
Quality of Life and Sexuality After Pelvic Exenteration for Gynecologic Cancer |
ENROLLING_BY_INVITATION | |
| NCT07584161 |
MH-ART vs CF-IMRT in Postoperative Cervical/Endometrial Cancer |
NOT_YET_RECRUITING | NA |
| NCT07583329 |
Comparison of Sentinel Lymph Node Applications in Endometrial Cancer Cases Performed With Vaginal Natural Orifice Transluminal Endoscopic Surgery (V-NOTES) and Conventional Laparoscopy |
NOT_YET_RECRUITING | |
| NCT07581288 |
Measurement of Urinary Hormones in Patients With Abnormal Uterine Bleeding to Study Uterine Cancer Progression |
NOT_YET_RECRUITING | |
| NCT07578649 |
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer |
NOT_YET_RECRUITING | PHASE3 |
| NCT07557225 |
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors |
RECRUITING | NA |
| NCT07555665 |
REal Word aPpLicAtion of Molecular Based Endometrial Cancer Classification |
RECRUITING | |
| NCT07544680 |
Endometrial Cancer Vaginal Fluid Specimen Collection Study |
RECRUITING |
